Anonymous
Guest
Anonymous
Guest
Errrr. 70k for the year??
That's what I was told from princeton one during the phone screen 70k/yr. I did not ask during the f2f as comp was not brought up.
Errrr. 70k for the year??
I also heard $70k at plan for Kythera. They try to sell on the upside potential, but with only one product which isn't even approved yet, and a high potential for getting bought out soon its just not worth it for me. A&C has been great for so far, and they are making good decisions. Plus, they are trying to clean up the mess left by Valeant.
your former president Stewart left the company with less than two years at the helm. Tells you everything you need to know. No future what so ever. When the top changes that fast and he was supposed to be the savior it tell you he knew the inside story and this place is no longer fixable.
Is Stewart no longer with G?
The point is related not to other cultures, but a lack of understanding by those in leadership positions of the U.S. market. Look at the ridiculous premium G paid for the aesthetics portfolio (which they already owned throughout the world).
Say what you want about MP at Valeant - if you had a company to run, and you wanted profitability - who would you hire him or HA? MP might not be a nice guy, but he knows a sucker when he sees one, especially one with a big checkbook backed by a Euro chocolate company. Valeant sold high - and now they are putting wrapping paper on Obagi for G to overpay once again. Truth!
Left Valeant right before G bought us ,the best thing ever Orphan drug company pay very good base and good bonus couldn't be happier .I was told G will cut everything in bonus and base.Galderma has been falling for awhile!